Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
ASX Announcement
QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C
Melbourne, Australia – 30 April 2024: Percheron Therapeutics Limited, an international
biotechnology company focused on the development of novel therapies for rare
diseases, is pleased to provide an update on the Company’s continuing progress during
the quarter ended 31 March 2024.
Key Points
•
ATL1102 phase IIb clinical trial approaches full recruitment. To date, 37 patients
have been randomised to the study, with a further 9 patients in screening.
•
Abstracts presented at international scientific conference. Three scientific
posters were presented at the Annual Meeting of the Muscular Dystrophy
Association in Orlando, FL, from 3 – 6 March 2024.
•
Receipt of R&D tax rebate for FY2023. The company received $1.576 million from
the Australian Tax Office in respect of the R&D Tax Incentive Rebate for the prior
financial year.
“The company continues to execute on its strategy,” commented Percheron CEO, Dr
James Garner. “Recruitment to the international phase IIb study of ATL1102 in Duchenne
muscular dystrophy is nearly complete, and we are making all efforts to be fully
recruited in May. Although the pace of recruitment has been a little slower than we
would have liked, we are pleased that all patients to date are remaining on study, and
the execution of the protocol has so far generally been of very high quality. In addition,
we were delighted to have no less than three abstracts on ATL1102 accepted to the
prestigious Annual Meeting of the Muscular Dystrophy Association, and the meeting
provided excellent opportunities for the Percheron team to network with clinicians,
business partners, and colleagues from other pharmaceutical companies working in the
field. As we look to the second quarter of CY2024, completion of recruitment to the
study will be our absolute first priority, and we will also be preparing for two important
international conferences in June.”
ATL1102 Phase IIb Clinical Trial Nearing Full Recruitment
As at the date of this report, the ongoing international phase IIb clinical trial of ATL1102
in the Duchenne muscular dystrophy (DMD) has randomised 37 out of a planned 45
patients. A further 9 patients are currently in screening, and several additional patients
have been identified by sites and are currently discussing participation.
Percheron Therapeutics Limited
ABN 41 095 060 745
ASX: PER | FSE: AWY | US OTC: ATHJY
10 patients have transitioned to the open-label extension phase of the study, after
successfully completing the blinded phase. The blinded phase represents the first six
months of the study and patients are randomised to receive one of two doses of
ATL1102 or placebo. The primary endpoint is assessed at completion of the blinded
phase. During the subsequent open-label phase, patients who originally received
placebo are re-randomised to receive one of two doses of ATL1102.
To date, no material safety concerns, and no significant operational issues, have
affected the conduct of the study.
The Company continues at this stage to anticipate final data in late CY2024 and will
provide further guidance to investors when full recruitment is reached.
Abstracts Presented at MDA Annual Meeting
The Company was pleased to have three scientific abstracts accepted to the Annual
Meeting of the Muscular Dystrophy Association, held in Orlando, FL, from 3 – 6 March
2024 1.
The titles of the abstracts were:
Poster V409 ATL1102 treatment of non-ambulant boys with DMD stabilizes function
modifying plasma proteins with roles in immune, fibrosis, bone & growth physiology
Poster V410 Mdx mice dosed with antisense to CD49d & dystrophin exon skip
morpholino; improved muscle force & affected pathways support ATL1102 combination
in DMD
Poster M149 Design of a Phase 2b study evaluating the efficacy and safety of ATL1102
in non-ambulant DMD
Copies of the respective poster presentations are available via the company website.
Receipt of R&D Tax Rebate for FY2023
On 12 February 2024, the Company announced that it had received from the Australian
Taxation Office an R&D Tax Incentive refund payment of $1,576,657 for the 30 June 2023
financial year 2. The amount received was in relation to the expenditure incurred on
eligible R&D activities undertaken in Australia and overseas.
Change of Company Address and Principal Place of Business
On 21 February 2024, the Company announced, in accordance with ASX Listing Rule
3.14, that it had changed its address to:
https://per.live.irmau.com/pdf/d811af58-6052-4818-8992-9c2d27cc0446/ATL1102-Data-presented-atMDA-Annual-Conference.pdf
2
https://per.live.irmau.com/pdf/19546ade-9407-40a0-9599-9c8db53afacc/Receipt-of-RD-Tax-incentivepayment.pdf
1
Page 2 of 4
L30, Collins Place,
35 Collins Street,
Melbourne, VIC 3000
Australia
The new location in the Melbourne central business district offers greater proximity to
investors and other stakeholders in Melbourne, as well as better access to transport and
other infrastructure. Moreover, the new office represents a significant cost saving in
relation to the company’s previous location.
Investor Engagement Activities
During 1Q CY2024, the Company commenced an ongoing program of investor
engagement, intended to raise awareness of the company among the investment
community.
The initiatives implemented in the current quarter include:
•
•
•
•
Redesign and relaunch of the company’s website
Shareholder ‘Open House’ meetings in Perth and Brisbane
Participation in Cantor Fitzgerald Virtual Duchenne Symposium
Video interview segment with Proactive Investors
The Company expects to continue and expand on these efforts in coming quarters.
Upcoming Conference Participation
Members of the Percheron team will attend the BIO Annual Convention in San Diego,
CA, from 3 – 6 June 2024. The Biotechnology Industry Organization (BIO) is the main
industry body for biotech companies, and the Annual Convention is a key partnering
conference. The company aims to build upon connections and engagements initiated at
previous meetings, including the JP Morgan Healthcare Conference, held in San
Francisco, CA, during January 2024.
Percheron will also be attending and sponsoring the 30th Annual Conference of Parent
Project Muscular Dystrophy (PPMD), a key US-based organisation focused on patient
advocacy and support. The Conference will be held in Orlando, FL, from 27 – 30 June
2024. The company aims to use the conference to connect with clinicians, researchers,
and patient advocates, as well as with other companies focused on the DMD
therapeutic area.
Financial Position
As noted in the accompanying unaudited quarterly cashflow report, the Company
closed the March 2024 quarter with a cash balance of $14.9 million, versus $17.2 million
at the end of the previous quarter.
Page 3 of 4
During the quarter the Company made payments to related parties of the entity and their
associates as disclosed in Item 6 of the Appendix 4C amounting to approximately
$205,072. The payments are related to salaries, directors' fees, and consulting fees on
normal commercial terms.
Based on a forward-looking cashflow forecast, the Company continues to project cash
runway into CY2025.
~ ENDS ~
About Percheron Therapeutics Limited
Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJY | FSE: AWY] is a publicly listed
biotechnology company focused on the development and commercialisation of novel therapies
for rare diseases. The company’s lead program is ATL1102, an antisense oligonucleotide
targeting the CD49d receptor. ATL1102 is currently the subject of an ongoing international phase
IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy
(DMD), for which data is expected in 2H CY2024. The drug has previously reported promising
results from an exploratory phase IIa study in the same population and has been awarded
orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.
For more information, please contact info@PercheronTx.com.
This announcement has been authorized for release to the Australian Securities Exchange
by the Board of Directors.
Page 4 of 4
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Percheron Therapeutics Limited
ABN
Quarter ended (“current quarter”)
41 095 060 745
31 March 2024
Consolidated statement of cash flows
Current quarter
$A’000
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Year to date
(9 months)
$A’000
-
-
(2,959)
(5,934)
-
-
(c) advertising and marketing
(7)
(86)
(d) leased assets
(45)
(98)
(e) staff costs
(478)
(1,498)
(f)
(530)
(1,655)
-
-
155
463
(a) research and development
(b) product manufacturing and operating
costs
administration and corporate costs
1.3
Dividends received (see note 3)
1.4
Interest received
1.5
Interest and other costs of finance paid
-
-
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
1,577
1,577
1.8
Other (provide details if material)
32
139
1.9
Net cash from / (used in) operating
activities
(2,255)
(7,092)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
2.2
Current quarter
$A’000
Year to date
(9 months)
$A’000
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
other non-current assets
Proceeds from disposal of:
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
-
-
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
-
11,612
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
-
(548)
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
-
-
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9
Other (provide details if material)
-
-
3.10
Net cash from / (used in) financing
activities
-
11,064
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
4.3
Current quarter
$A’000
Year to date
(9 months)
$A’000
17,194
10,967
(2,255)
(7,092)
Net cash from / (used in) investing activities
(item 2.6 above)
-
-
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
-
11,064
4.5
Effect of movement in exchange rates on
cash held
-
-
4.6
Cash and cash equivalents at end of
period
14,939
14,939
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
939
694
5.2
Call deposits
14,000
16,500
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
14,939
17,194
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
205
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
-
Current quarter
$A'000
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1
Loan facilities
-
-
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
-
-
7.4
Total financing facilities
-
-
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
8.
Estimated cash available for future operating activities
8.1
Net cash from / (used in) operating activities (item 1.9)
(2,255)
8.2
Cash and cash equivalents at quarter end (item 4.6)
14,939
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
-
$A’000
14,939
7
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: N/A
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: N/A
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: N/A
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
30 April 2024
Authorised by: By the Board
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover